On-demand therapy (ODT) in Parkinson’s disease: a survey of advanced practice providers
Objective: A survey of neurology Advanced Practice Providers (APPs) provides insights into their perspectives on managing and treating patients with Parkinson’s disease (PD) in the…Placebo response in Parkinson’s disease (PD) is predicted by expression levels of a specific brain network
Objective: To determine whether baseline expression levels for the previously validated sham surgery-related metabolic pattern (SSRP) can be used to predict the magnitude of the…Exercise and levodopa metabolism in Parkinson disease
Objective: The aim of our paper was to assess if standard physical exercise may change pharmacokinetics of levodopa/benserazide in patients with and without prior exposure…Real-World Utilization of Istradefylline Among Patients with Parkinson’s Disease
Objective: This study examined real-world utilization of istradefylline and other PD-related medications before and after istradefylline initiation. Background: Istradefylline is indicated as adjunctive therapy to…Understanding patient perceptions of advanced Parkinson’s disease (aPD) treatments
Objective: To explore patients’ perceptions of treatment options for aPD and treatment decision considerations. Background: As PD advances, some people with Parkinson’s (PwP) on oral…Alopecia in females with young onset Parkinson’s Disease: an exploratory survey
Objective: To explore the symptoms of females with young onset Parkinson's Disease (YOPD), specifically alopecia, in comparison to females with traditional onset Parkinson’s Disease (TOPD).…The mGlu2 positive allosteric modulator AZD8529 alleviates L-DOPA-induced dyskinesia and psychosis-like behaviours in the parkinsonian marmoset
Objective: To assess the effect of the metabotropic glutamate 2 (mGlu2) receptor positive allosteric modulator (PAM) AZD8529 on L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia and psychosis-like behaviours (PLBs)…Clinical analysis of Levodopa/carbidopa intestinal gel infusion in advanced Parkinson’s disease. A single-center retrospective cohort study.
Objective: To evaluate clinical impact of treatment (LCIG) infusion in patients with advanced PD. Background: Levodopa/carbidopa intestinal gel (LCIG) infusion has demonstrated more stable plasma…Integrated analysis of phase 3 trials of foslevodopa/foscarbidopa demonstrated that majority of reported infusion site AEs including infections were non serious, mild to moderate in severity and did not result in treatment discontinuation.
Objective: To characterize reported infusion site infection adverse events (AEs) and their clinical management in patients with Parkinson’s disease (PD) treated with foslevodopa/foscarbidopa (LDP/CDP). Background:…Pharmacological combinations in early stages of Parkinson’s disease and association with motor complications
Objective: To describe the different combinations of dopaminergic drugs at the early stage of Parkinson’s disease (PD) in a real-life cohort, and to determine their…
- 1
- 2
- 3
- …
- 29
- Next Page »